Neurocrine biosciences to present new phase 3 cahtalyst™ data in adult and pediatric patients with cah and study data for modified-release hydrocortisone in primary adrenal insufficiency and cah at endo 2024

New cahtalyst™ pediatric and cahtalyst™ adult phase 3 clinical study data in congenital adrenal hyperplasia cahtalog™ registry data highlighting impact of supraphysiologic glucocorticoid dosing phase 2 (champain) study data for mrhc vs. plenadren in primary adrenal insufficiency long-term study data for mrhc in adults with cah san diego , may 28, 2024 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced that it will present key information from its neuroendocrinology pipeline, including new phase 3 clinical study data from its cahtalyst™ registrational studies of crinecerfont in pediatric and adult patients with classic congenital adrenal hyperplasia (cah) due to 21-hydroxylase deficiency and data from its modified-release hydrocortisone (mrhc) studies in primary adrenal insufficiency and cah.
NBIX Ratings Summary
NBIX Quant Ranking